< previous page page_xviii next page >

Page xviii
James E. Higgins, Ph.D. Executive Vice President and Director of Biometrics, Health Decisions, Inc., Chapel Hill, North Carolina
Karolyn Jackson, Ph.D. Clinical Pathology Laboratory, Zeneca Pharmaceuticals, Cheshire, England
Agis Kydonieus, Ph.D. Vice President, R & D, ConvaTec, A Bristol-Myers Squibb Company, Princeton, New Jersey
Gary D. Lightfoot Senior Vice President of Market Development, Pharmaco International Inc., Austin, Texas
Michael C. Makoid, Ph.D. Associate Professor of Pharmaceutical Sciences, School of Pharmacy & Allied Health Professions, Creighton University, Omaha, Nebraska
Vaila M. Marshall Senior Director of Regulatory Affairs and Clinical Quality Assurance, Pfizer Central Research, Kent, England
J. Robert Powell, Pharm.D. International Director, Clinical Pharmacology, Glaxo-Wellcome Inc., Research Triangle Park, North Carolina
Paul D. Rubin, Ph.D. Vice-President, Glaxo-Wellcome Inc., Research Triangle Park, North Carolina
Martha M. Rumore, Pharm.D. Associate Professor, Pharmacy Administration, Arnold & Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, New York
Albert J. Siemens, Ph.D. Executive Vice President, Clin Trials Research Inc., Research Triangle Park, North Carolina
John C. Somberg, M.D. Professor of Medicine and Pharmacology, and Chief of the Division of Clinical Pharmacology and Cardiology, Finch University of Health Sciences/The Chicago Medical School, North Chicago, Illinois
Terry R. Stouch, Ph.D. Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey
John Thompson, M.A. Senior Advisor, CSC Index, Cambridge, Massachusetts
John R. Vogel, Ph.D. Drug Development Consultant, John R. Vogel Associates, Inc., Oldwick, New Jersey
Peter G. Welling, Ph.D. Vice President, Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research, Warner-Lambert Company, Ann Arbor, Michigan

 
< previous page page_xviii next page >